ERFSF Stock Recent News

Eurofins Scientific faced a short attack by Muddy Waters but has since recovered, maintaining strong financials and cash flow despite the initial share price drop. The company reported a net profit of 220.7M EUR and an attributable net free cash flow of 217M EUR in H1, supporting its financial health. Eurofins aims for 1.55B EUR in EBITDA for 2024 and 2.4B EUR by 2027, showing confidence in its long-term growth strategy.

EUROFINS SCIENT (ERFSF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Eurofins Scientific SE (OTCPK:ERFSF) Q2 2024 Earnings Call July 24, 2024 9:00 AM ET Company Participants Gilles Martin - Chief Executive Officer Laurent Lebras - Chief Financial Officer Conference Call Participants Suhasini Varanasi - Goldman Sachs Himanshu Agarwal - Bank of America Neil Tyler - Redburn Atlantic Arthur Truslove - Citi James Rose - Barclays Allen Wells - Jefferies Delphine Le Louet - Bernstein Operator Ladies and gentlemen, welcome and thank you for joining Eurofins Half Year 2024 Results Call. Please note that this call is being recorded and will later be available for replay on the Eurofins Investor Relations website.

EUROFINS SCIENT (ERFSF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Eurofins Scientific is delivering a 10% growth without relying on exuberant COVID-related margins. The company boasts a robust business model, a significant market share, and a reliable and trustworthy management team. The stock has the potential to double by 2028 if the management projections are achieved.

Eurofins Scientific: The Normalization Of COVID-Related Sales Presents An Opportunity

Eurofins is dealing with a revenue decrease due to the lack of COVID testing and the sale of reagents. Excluding the COVID-related revenue, the H1 2023 revenue would have increased by a high single digit percentage. The company slightly reduced its 2023 FCF guidance to around 700M EUR but reconfirmed the 2027 guidance.

We present an overview of the testing, inspection, and certification (TIC) market. We highlight the different strategies that have been pursued by the main 4 players over time.

Eurofins Scientific SE (OTCPK:ERFSF) Q4 2022 Results Conference Call March 1, 2023 9:00 AM ET Company Participants Dr. Gilles Martin - Chairman and Chief Executive Officer Laurent Lebras - Chief Financial Officer Conference Call Participants Suhasini Varanasi - Goldman Sachs Shivani Gupta - HSBC Del Le Louet - SocieteGenerale Allen Wells - Jefferies James Rose - Barclays Dominic Edridge - Deutsche Bank Arthur Truslove - Citi Operator Ladies and gentlemen, welcome, and thank you for joining Eurofins' Full Year 2022 Results Call. Please note that this call is being recorded and will be available later for replay on the Eurofins Investor Relations website.

Eurofins Scientific printed cash during the COVID pandemic as its testing capacity was running at full utilization. There shouldn't be any massive post-COVID blues as growth in other domains should offset the decreasing COVID-related revenue.